Ask AI

Novel Targeted Therapies for PIK3CA/AKT1/PTEN-Altered Metastatic Breast Cancer: Key Evidence and Real-world Insights to Optimize Patient Care

Gain global expert insights into PI3K/AKT/mTOR pathway inhibitor use in the management of HR+/HER2- metastatic breast cancer to optimize patient outcomes and minimize therapy-related toxicities, through commentaries, podcasts, Interactive Case Challenges, an Interactive Decision Support Tool, and a downloadable infographic.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd.